In the field of molecular oncology, microRNAs (miRNAs) and their role in regulating
physiological processes and cancer pathogenesis have been a revolutionary discovery over …

Breast cancer is the most frequently diagnosed malignancy in American women. While
significant progress has been made in the development of modern diagnostic tools and …

RNA interference (RNAi) as a mechanism to selectively degrade mRNA (mRNA) expression
has emerged as a potential novel approach for drug target validation and the study of …

Multidrug resistance (MDR) is one of the major barriers in cancer chemotherapy. P-
glycoprotein (P-gp), a cell membrane protein in MDR, also a member of ATP-Binding …

Small interfering RNAs (siRNAs) technology has emerged as a promising potential
treatment for viral, genetic diseases and cancers. Despite the powerful therapeutic potential …

To use siRNA (small interfering ribonucleic acids) for systemic administration, a delivery
system is often necessary to overcome barriers between administration and the target sites …

RNA interference (RNAi) is a gene regulation mechanism initiated by RNA molecules that
enables sequence‐specific gene silencing by promoting degradation of specific mRNAs …

RNA interference (RNAi) is considered a highly specific approach for gene silencing and
holds tremendous potential for treatment of various pathologic conditions such as …

Recent progress in RNA biology has broadened the scope of therapeutic targets of RNA
drugs for cancer therapy. However, RNA drugs, typically small interfering RNAs (siRNAs) …

Nanoparticles (NPs) formulated with cationic lipids and/or polymers have shown substantial
potential for systemic delivery of RNA therapeutics such as small interfering RNA (siRNA) for …